Ever exposed [N = 443] | No biologic exposure [N = 112] | Previous biologic exposure [N = 331] | |
Baricitinib | 374 (84%) | 103 (28%) | 271 (72%) |
Tofacitinib | 69 (16%) | 9 (13%) | 60 (87%) |
Age (years) | 61 (53 to 69) | 62 (51 to 71) | 61 (53 to 69) |
Female | 335 (76%) | 81 (72%) | 254 (77%) |
Disease duration (years) | 12 (6 to 21) | 6 (3 to 15) | 14 (8 to 22) |
Number of previous biologics | - | - | 3 (2 to 4) |
No prior biologics1 prior biologic>2 prior biologicsUnknown | 112 (25%)63 (14%)211 (48%)57 (13%) | 112 (100%)--- | 0 (0%)63 (19%)211 (64%)57 (17%) |
Type of previous biologic exposure | - | - | - |
TNF inhibitorRituximabAbataceptTocilizumab | ---- | ---- | 248 (91%)143 (52%)95 (35%)139 (51%) |
Concurrent Methotrexate | 185 (43%) | 51 (48%) | 134 (42%) |
Concurrent oral steroids | 133 (31%) | 22 (21%) | 111 (34%) |
Comorbidities# | - | - | - |
None1 comorbidity2+ comorbidities | 170 (38%)125 (28%)148 (34%) | 58 (52%)25 (22%)29 (26%) | 112 (34%)100 (30%)119 (36%) |
Prior Cancer | 38 (9%) | 15 (15%) | 23 (7%) |
Pulmonary Fibrosis | 11 (4%) | 3 (3%) | 8 (4%) |
DAS28 | 5.7 (5.1 to 6.4) | 5.6 (5.2 to 6.2) | 5.8 (5.0 to 6.6) |
HAQ | 2 (1.4 to 2.5) | 1.9 (0.9 to 2.4) | 2.1 (1.5 to 2.6) |
Results presented as N (%) or median (IQR).#Comorbidities - hypertension, ischaemic heart disease, stroke, lung disease (asthma and COPD), renal disease, diabetes, depression, liver disease.